Brokerages Set Krystal Biotech, Inc. (NASDAQ:KRYS) Price Target at $210.75

Key Points

• Analysts have given Krystal Biotech, Inc. (NASDAQ:KRYS) an average rating of "Buy", with one strong buy, seven buy, and one hold rating among them.
• The average twelve-month price objective set by brokerages for Krystal Biotech is $210.75, with price targets ranging from $166.00 to $240.00
• Krystal Biotech reported $1.29 earnings per share for the last quarter, exceeding the consensus estimate of $1.08, along with revenue of $96.04 million.

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) has been given an average rating of "Buy" by the nine brokerages that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $210.75.

A number of equities research analysts recently weighed in on KRYS shares. Chardan Capital reiterated a "buy" rating and set a $219.00 price objective on shares of Krystal Biotech in a report on Tuesday, August 5th. Bank of America decreased their price objective on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a report on Tuesday, July 22nd. Guggenheim decreased their price objective on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Citigroup reiterated a "neutral" rating and set a $166.00 price objective (down previously from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. Finally, HC Wainwright reiterated a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a report on Friday, July 25th.

Krystal Biotech Trading Down 1.1%

Shares of KRYS stock traded down $1.67 during trading hours on Thursday, reaching $148.60. 55,356 shares of the stock were exchanged, compared to its average volume of 332,685. Krystal Biotech has a 12-month low of $122.80 and a 12-month high of $207.84. The company's 50-day moving average price is $143.40 and its 200-day moving average price is $155.00. The firm has a market capitalization of $4.30 billion, a price-to-earnings ratio of 30.32 and a beta of 0.70.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $1.29 EPS for the quarter, topping analysts' consensus estimates of $1.08 by $0.21. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. The firm had revenue of $96.04 million during the quarter, compared to analysts' expectations of $95.42 million. On average, sell-side analysts expect that Krystal Biotech will post 6.14 EPS for the current year.

Insider Activity

In other news, insider Suma Krishnan sold 13,435 shares of the stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the transaction, the insider directly owned 1,443,276 shares in the company, valued at approximately $216,924,382.80. This trade represents a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 49,800 shares of company stock worth $7,487,943 in the last 90 days. 13.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Fifth Third Bancorp raised its stake in shares of Krystal Biotech by 159.1% during the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after acquiring an additional 105 shares in the last quarter. GAMMA Investing LLC grew its position in Krystal Biotech by 179.3% during the 1st quarter. GAMMA Investing LLC now owns 673 shares of the company's stock worth $121,000 after purchasing an additional 432 shares during the last quarter. Wells Fargo & Company MN grew its position in Krystal Biotech by 21.3% during the 4th quarter. Wells Fargo & Company MN now owns 16,928 shares of the company's stock worth $2,652,000 after purchasing an additional 2,972 shares during the last quarter. Oppenheimer Asset Management Inc. purchased a new stake in Krystal Biotech during the 1st quarter worth approximately $229,000. Finally, M&T Bank Corp purchased a new stake in Krystal Biotech during the 1st quarter worth approximately $667,000. Institutional investors own 86.29% of the company's stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).